{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:40Z","timestamp":1767135100446,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd012577","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000}}],"reference-count":75,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012577.pub2","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T15:45:10Z","timestamp":1545147910000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis"],"prefix":"10.1002","volume":"2018","author":[{"given":"Robert J","family":"Barry","sequence":"first","affiliation":[{"name":"College of Medical and Dental Sciences, University of Birmingham; Academic Unit of Ophthalmology, Institute of Inflammation and Ageing; Birmingham UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad O","family":"Tallouzi","sequence":"additional","affiliation":[{"name":"University of Birmingham; Institute of Applied Health Research, College of Medical and Dental Sciences; Birmingham UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Bucknall","sequence":"additional","affiliation":[{"name":"Shrewsbury UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M","family":"Mathers","sequence":"additional","affiliation":[{"name":"University of Birmingham; Institute of Applied Health Research, College of Medical and Dental Sciences; Birmingham UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip I","family":"Murray","sequence":"additional","affiliation":[{"name":"College of Medical and Dental Sciences, University of Birmingham; Academic Unit of Ophthalmology, Institute of Inflammation and Ageing; Birmingham UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie J","family":"Calvert","sequence":"additional","affiliation":[{"name":"University of Birmingham; Centre for Patient Reported Outcomes Research, Institute of Applied Health Research; Birmingham UK B15 2TT"},{"name":"University Hospitals Birmingham NHS Foundation Trust and University of Birmingham; NIHR Birmingham Biomedical Research Centre and NIHR Surgical Reconstruction and Microbiology Research Centre; Birmingham UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Moore","sequence":"additional","affiliation":[{"name":"University of Birmingham; Institute of Applied Health Research; Public Health Building Edgbaston Birmingham West Midlands UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair K","family":"Denniston","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust; Department of Ophthalmology; Birmingham UK B15 2WB"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD012577.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10050","key":"10.1002\/14651858.CD012577.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/509456","article-title":"Uveitis in the aging eye: incidence, patterns, and differential diagnosis","volume":"2015","author":"Abdulaal Marwan","year":"2015","journal-title":"Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD012577.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaophthalmol.2013.4237","article-title":"Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study","volume":"131","author":"Acharya","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD012577.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ophtha.2014.01.007","article-title":"Development and validation of quality-of-life questionnaires for birdshot chorioretinopathy","volume":"121","author":"Barry","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0002-9394(14)74235-7","article-title":"International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease","volume":"103","author":"Bloch-Michel","year":"1987","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD012577.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.122.3.330","article-title":"Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography","volume":"122","author":"Brown","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD012577.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/eye.2011.320","article-title":"Adalimumab specifically induces CD3+ CD4+ CD25high Foxp3+ CD127\u2212 T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study","volume":"26","author":"Calleja","year":"2012","journal-title":"Eye"},{"issue":"12","key":"10.1002\/14651858.CD012577.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et's disease: a 1-year follow-up study of 124 patients","volume":"53","author":"Calvo-R\u00edo","year":"2014","journal-title":"Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD012577.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Survey of Ophthalmology"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0011|cit11","unstructured":"Veritas Health Innovation Covidence"},{"issue":"6","key":"10.1002\/14651858.CD012577.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/ICU.0b013e32801094b5","article-title":"Inflammatory mediators of uveitis: cytokines and chemokines","volume":"17","author":"Curnow","year":"2006","journal-title":"Current Opinion in Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0013|cit13","first-page":"60","article-title":"Current concepts in the management of uveitic macular edema","volume":"17","author":"Davis","year":"2010","journal-title":"Johns Hopkins Advanced Studies in Ophthalmology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD012577.pub2-BIB0014|cit14","first-page":"S51","article-title":"The role of steroids in the management of uveitic macular edema","volume":"21","author":"Smet","year":"2010","journal-title":"European Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD012577.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273940801899822","article-title":"International Uveitis Study Group (IUSG) clinical classification of uveitis","volume":"16","author":"Deschenes","year":"2008","journal-title":"Ocular Immunology and Inflammation"},{"issue":"7","key":"10.1002\/14651858.CD012577.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/bjo.2008.153874","article-title":"Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis","volume":"93","author":"Deuter","year":"2009","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD012577.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000078612","article-title":"Uveitis: a potentially blinding disease","volume":"218","author":"Durrani","year":"2004","journal-title":"Ophthalmologica"},{"issue":"5","key":"10.1002\/14651858.CD012577.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2011","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD012577.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ceo.12207","article-title":"Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series","volume":"42","author":"Faez","year":"2014","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"Suppl","key":"10.1002\/14651858.CD012577.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2005.09.006","article-title":"Anti-TNF therapy: where have we got to in 2005?","volume":"25","author":"Feldmann","year":"2005","journal-title":"Journal of Autoimmunity"},{"issue":"5","key":"10.1002\/14651858.CD012577.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.4049\/jimmunol.168.5.2483","article-title":"Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation","volume":"168","author":"Foxman","year":"2002","journal-title":"Journal of Immunology"},{"issue":"34","key":"10.1002\/14651858.CD012577.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"22128","DOI":"10.1074\/jbc.273.34.22128","article-title":"Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells","volume":"273","author":"Giraudo","year":"1998","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0023|cit23","first-page":"1360","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0024|cit24","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"3","key":"10.1002\/14651858.CD012577.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"issue":"1-2","key":"10.1002\/14651858.CD012577.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2005.09.018","article-title":"Sequential induction of angiogenic growth factors by TNF-\u03b1 in choroidal endothelial cells","volume":"171","author":"Hangai","year":"2006","journal-title":"Journal of Neuroimmunology"},{"issue":"12","key":"10.1002\/14651858.CD012577.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Behcet disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD012577.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0030|cit30","unstructured":"Higgins JP Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychological Methods"},{"issue":"5","key":"10.1002\/14651858.CD012577.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0002-9394(01)00830-3","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"131","author":"Jabs","year":"2001","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0033|cit33","first-page":"311","article-title":"Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (An AOS Thesis)","volume":"107","author":"Kaiser","year":"2009","journal-title":"Transactions of the American Ophthalmological Society"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2147\/OPTH.S40268","article-title":"Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis","volume":"7","author":"Karim","year":"2013","journal-title":"Clinical Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clinical Immunology"},{"issue":"9","key":"10.1002\/14651858.CD012577.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.ophtha.2013.01.069","article-title":"Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema","volume":"120","author":"Kempen","year":"2013","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD012577.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1916. e1-1916.e","DOI":"10.1016\/j.ophtha.2005.06.009","article-title":"Outcome of intravitreal triamcinolone in uveitis","volume":"112","author":"Kok","year":"2005","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD012577.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","article-title":"Impact of macular edema on visual acuity in uveitis","volume":"113","author":"Lardenoye","year":"2006","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD012577.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1517\/14712598.2014.947957","article-title":"A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II","volume":"14","author":"Lee","year":"2014","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"15","key":"10.1002\/14651858.CD012577.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1517\/14656566.2014.948417","article-title":"A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I","volume":"15","author":"Lee","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0041|cit41","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2013.09.023","article-title":"Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema","volume":"121","author":"Levin","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD012577.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"American Journal of Ophthalmology"},{"issue":"7234","key":"10.1002\/14651858.CD012577.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/bmj.320.7234.555","article-title":"Regular review: management of chronic uveitis","volume":"320","author":"McCluskey","year":"2000","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocular Immunology and Inflammation"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","article-title":"Long-term treatment with golimumab for severe uveitis","volume":"22","author":"Miserocchi","year":"2014","journal-title":"Ocular Immunology and Inflammation"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"International Journal of Surgery"},{"issue":"6","key":"10.1002\/14651858.CD012577.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archopht.122.6.845","article-title":"Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis","volume":"122","author":"Murphy","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD012577.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10792-008-9200-z","article-title":"Long-term control of cystoid macular oedema in noninfectious uveitis with mycophenolate mofetil","volume":"29","author":"Neri","year":"2008","journal-title":"International Ophthalmology"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0050|cit50","unstructured":"National Institute for Health and Care Excellence Adalimumab and dexamethasone for treating non-infectious uveitis www.nice.org.uk\/guidance\/ta460"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12348-014-0026-8","article-title":"Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders","volume":"4","author":"Pascual-Camps","year":"2014","journal-title":"Journal of Ophthalmic Inflammation and Infection"},{"issue":"10","key":"10.1002\/14651858.CD012577.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD012577.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4103\/0301-4738.114090","article-title":"Uveitis in developing countries","volume":"61","author":"Rao","year":"2013","journal-title":"Indian Journal of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD012577.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00347-004-0996-2","article-title":"Optical coherence tomography in the diagnosis and follow-up of patients with uveitic macular edema","volume":"101","author":"Reinthal","year":"2004","journal-title":"Ophthalmologe"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0055|cit55","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"4","key":"10.1002\/14651858.CD012577.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD012577.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012577.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-\u03b1 monoclonal antibody cA2 binds recombinant transmembrane TNF-\u03b1 and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD012577.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00417-013-2552-8","article-title":"Anti-TNF-\u03b1 agents for refractory cystoid macular edema associated with noninfectious uveitis","volume":"252","author":"Schaap-Fogler","year":"2014","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD012577.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012577.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/09273940903072443","article-title":"Clinical review: anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience","volume":"17","author":"Sharma","year":"2009","journal-title":"Ocular Immunology and Inflammation"},{"issue":"5","key":"10.1002\/14651858.CD012577.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/09273948.2011.592260","article-title":"Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema","volume":"19","author":"Sreekantam","year":"2011","journal-title":"Ocular Immunology and Inflammation"},{"issue":"3","key":"10.1002\/14651858.CD012577.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s10792-017-0592-5","article-title":"Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy","volume":"38","author":"Steeples","year":"2018","journal-title":"International Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD012577.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ajo.2008.09.014","article-title":"Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest","volume":"146","author":"Suhler","year":"2008","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD012577.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/286857","article-title":"Off-label uses of anti-TNF therapy in three frequent disorders: Beh\u00e7et's disease, sarcoidosis, and noninfectious uveitis","volume":"2013","author":"S\u00e1nchez-Cano","year":"2013","journal-title":"Mediators of Inflammation"},{"issue":"1","key":"10.1002\/14651858.CD012577.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/imt.12.134","article-title":"A systematic review of biologics for the treatment of noninfectious uveitis","volume":"5","author":"Takeuchi","year":"2013","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1002\/14651858.CD012577.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ophtha.2008.10.033","article-title":"Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema","volume":"116","author":"Taylor","year":"2009","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD012577.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/ICO.0b013e318211400a","article-title":"Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis","volume":"31","author":"Tlucek","year":"2012","journal-title":"Cornea"},{"issue":"2","key":"10.1002\/14651858.CD012577.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00810249","article-title":"Immunosuppression in uveitis therapy","volume":"21","author":"Gelder","year":"1999","journal-title":"Springer Seminars in Immunopathology"},{"issue":"1","key":"10.1002\/14651858.CD012577.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajo.2006.02.052","article-title":"Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema","volume":"142","author":"Kooij","year":"2006","journal-title":"American Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD012577.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/09273940802209153","article-title":"Comparison of the efficacy and safety of different methods of posterior subtenon injection","volume":"16","author":"Venkatesh","year":"2008","journal-title":"Ocular Immunology and Inflammation"},{"issue":"1","key":"10.1002\/14651858.CD012577.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/bjo.2006.101386","article-title":"The prevalence of sight-threatening uveitis in Scotland","volume":"91","author":"Williams","year":"2007","journal-title":"British Journal of Ophthalmology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012577.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1007\/BF01778294","article-title":"The influence of a peptide sequence from PF-4 (CT-112) on type II collagen-induced arthritis in mice","volume":"44","author":"Wooley","year":"1995","journal-title":"Inflammation Research"},{"issue":"4","key":"10.1002\/14651858.CD012577.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012577","article-title":"Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis","author":"Tallouzi","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012577.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T06:25:00Z","timestamp":1629786300000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012577.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":75,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012577.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]}}}